<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00767000</url>
  </required_header>
  <id_info>
    <org_study_id>0941-007</org_study_id>
    <secondary_id>2008_557</secondary_id>
    <nct_id>NCT00767000</nct_id>
  </id_info>
  <brief_title>Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)</brief_title>
  <official_title>A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effect of MK-0941 as add-on therapy for participants
      taking insulin for type 2 diabetes mellitus. The primary hypotheses of this study are that
      treatment with MK-0941 added to insulin will provide greater reduction in hemoglobin A1c
      (HbA1c) level than will placebo added to insulin at 14 weeks, and that MK-0941 will be
      well-tolerated at 1 or more doses that demonstrate efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 54-week randomized, double-blind base study with an optional 104-week
      extension study (MK-0941-007-11). Beginning on Week 16, participants not randomized to the
      maximum dose of MK-0941 could up-titrate to MK-0941 40 mg three times daily. Participants who
      complete the 54-week base study are eligible to enter the extension study and will remain in
      the treatment group to which they were assigned in the base study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin A1c (HbA1c) Level</measure>
    <time_frame>Baseline and Weeks 14, 54, 106, and 158</time_frame>
    <description>Least square means change from baseline in HbA1c. HbA1c represents the percentage of glycated hemoglobin. A negative number means reduction in HbA1c level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced at Least One Adverse Event</measure>
    <time_frame>Entire study including 54-week study and 104-week extension</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event</measure>
    <time_frame>Entire study including 54-week study and 104-week extension</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Two-hour Post Meal Glucose Level</measure>
    <time_frame>Baseline and Weeks 14, 54, 106, and 158</time_frame>
    <description>Least squares mean change from baseline in 2-hour post meal glucose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Fasting Plasma Glucose Level</measure>
    <time_frame>Baseline and Weeks 14, 54, 106, and 158</time_frame>
    <description>Least squares mean change from baseline in fasting plasma glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve an HbA1c of &lt;7.0%</measure>
    <time_frame>Weeks 106 and 158</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an HbA1c of &lt;7.0% at Week 54 Who Maintain an HbA1c of &lt;7.0%</measure>
    <time_frame>Weeks 54, 106 and 158</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">813</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>MK-0941 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0941 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0941 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0941 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0941</intervention_name>
    <description>MK-0941 tablets three times daily</description>
    <arm_group_label>MK-0941 10 mg</arm_group_label>
    <arm_group_label>MK-0941 20 mg</arm_group_label>
    <arm_group_label>MK-0941 30 mg</arm_group_label>
    <arm_group_label>MK-0941 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Matching placebo to MK-0941 three times daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lantus</intervention_name>
    <description>Lantus injection once daily</description>
    <arm_group_label>MK-0941 10 mg</arm_group_label>
    <arm_group_label>MK-0941 20 mg</arm_group_label>
    <arm_group_label>MK-0941 30 mg</arm_group_label>
    <arm_group_label>MK-0941 40 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Insulin glargine injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.</description>
    <arm_group_label>MK-0941 10 mg</arm_group_label>
    <arm_group_label>MK-0941 20 mg</arm_group_label>
    <arm_group_label>MK-0941 30 mg</arm_group_label>
    <arm_group_label>MK-0941 40 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  has type 2 diabetes mellitus

          -  has body mass index &gt;20 and &lt;43 kg/m^2

          -  is a male, or a female who is unlikely to conceive

          -  currently on a stable dose of insulin with or without metformin for Type 2 diabetes
             mellitus

        Extension Study Inclusion Criteria:

          -  completed the base study either on double-blind study medication or as part of the
             post-treatment follow up population

          -  had ≥85% compliance with double-blind and open-label medication during the base study
             double-blind treatment period

        Exclusion Criteria:

          -  has any history of Type 1 diabetes mellitus or ketoacidosis

          -  has received more that 1 week of thiazolidinedione (such as pioglitazone or
             rosiglitazone) therapy or injectable increatin-based therapy (such as Byetta) within
             the prior 8 weeks

          -  has had ≥2 episodes during their lifetime or &gt;1 episode within the past year resulting
             in hypoglycemic seizures, comas, or unconsciousness

          -  is on a weight loss program and is not in the maintenance phase, or patient is taking
             a weight loss medication (e.g., orlistat, sibutramine, rimonabant) within 8 weeks of
             Visit 1

          -  has undergone surgery within 30 days prior to Visit 1 or has planned major surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Jordan</country>
    <country>Korea, Republic of</country>
    <country>Lebanon</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Meininger GE, Scott R, Alba M, Shentu Y, Luo E, Amin H, Davies MJ, Kaufman KD, Goldstein BJ. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care. 2011 Dec;34(12):2560-6. doi: 10.2337/dc11-1200. Epub 2011 Oct 12.</citation>
    <PMID>21994424</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2008</study_first_submitted>
  <study_first_submitted_qc>October 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2008</study_first_posted>
  <results_first_submitted>June 19, 2012</results_first_submitted>
  <results_first_submitted_qc>July 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 3, 2012</results_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MK-0941 10 mg</title>
          <description>MK-0941 10 mg three times daily plus insulin once daily with or without metformin</description>
        </group>
        <group group_id="P2">
          <title>MK-0941 20 mg</title>
          <description>MK-0941 20 mg three times daily plus insulin once daily with or without metformin</description>
        </group>
        <group group_id="P3">
          <title>MK-0941 30 mg</title>
          <description>MK-0941 30 mg three times daily plus insulin once daily with or without metformin</description>
        </group>
        <group group_id="P4">
          <title>MK-0941 40 mg</title>
          <description>MK-0941 40 mg three times daily plus insulin once daily with or without metformin</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo three times daily plus insulin once daily with or without metformin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>54-week Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="117"/>
                <participants group_id="P3" count="117"/>
                <participants group_id="P4" count="229">Includes additional participants enrolled to enhance evaluation of the safety profile of MK-0941</participants>
                <participants group_id="P5" count="231">Includes additional participants enrolled to enhance evaluation of the safety profile of MK-0941</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="113"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="225"/>
                <participants group_id="P5" count="224"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Creaninine/creatinine clearance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hyperglycemia</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hypoglycemia</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Interruption of study medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="89"/>
                <participants group_id="P4" count="196"/>
                <participants group_id="P5" count="194"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not reported</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Optional 104-week Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7">The extension study was optional. Not all participants completing the 54-week study continued.</participants>
                <participants group_id="P2" count="3">The extension study was optional. Not all participants completing the 54-week study continued.</participants>
                <participants group_id="P3" count="7">The extension study was optional. Not all participants completing the 54-week study continued.</participants>
                <participants group_id="P4" count="2">The extension study was optional. Not all participants completing the 54-week study continued.</participants>
                <participants group_id="P5" count="4">The extension study was optional. Not all participants completing the 54-week study continued.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK-0941 10 mg</title>
          <description>MK-0941 10 mg three times daily plus insulin once daily with or without metformin</description>
        </group>
        <group group_id="B2">
          <title>MK-0941 20 mg</title>
          <description>MK-0941 20 mg three times daily plus insulin once daily with or without metformin</description>
        </group>
        <group group_id="B3">
          <title>MK-0941 30 mg</title>
          <description>MK-0941 30 mg three times daily plus insulin once daily with or without metformin</description>
        </group>
        <group group_id="B4">
          <title>MK-0941 40 mg</title>
          <description>MK-0941 40 mg three times daily plus insulin once daily with or without metformin</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo three times daily plus insulin once daily with or without metformin</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="119"/>
            <count group_id="B2" value="117"/>
            <count group_id="B3" value="117"/>
            <count group_id="B4" value="229"/>
            <count group_id="B5" value="231"/>
            <count group_id="B6" value="813"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>26 to 71 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="229"/>
                    <measurement group_id="B5" value="231"/>
                    <measurement group_id="B6" value="813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="123"/>
                    <measurement group_id="B5" value="115"/>
                    <measurement group_id="B6" value="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="106"/>
                    <measurement group_id="B5" value="116"/>
                    <measurement group_id="B6" value="397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hemoglobin A1c (HbA1c) Level</title>
        <description>Least square means change from baseline in HbA1c. HbA1c represents the percentage of glycated hemoglobin. A negative number means reduction in HbA1c level.</description>
        <time_frame>Baseline and Weeks 14, 54, 106, and 158</time_frame>
        <population>Full analysis set. The additional participants added to the MK-0941 40 mg and placebo arms to enhance evaluation of safety were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0941 10 mg</title>
            <description>MK-0941 10 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O2">
            <title>MK-0941 20 mg</title>
            <description>MK-0941 20 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O3">
            <title>MK-0941 30 mg</title>
            <description>MK-0941 30 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O4">
            <title>MK-0941 40 mg</title>
            <description>MK-0941 40 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo three times daily plus insulin once daily with or without metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin A1c (HbA1c) Level</title>
          <description>Least square means change from baseline in HbA1c. HbA1c represents the percentage of glycated hemoglobin. A negative number means reduction in HbA1c level.</description>
          <population>Full analysis set. The additional participants added to the MK-0941 40 mg and placebo arms to enhance evaluation of safety were not included in the analysis.</population>
          <units>Percent HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="118"/>
                <count group_id="O5" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" lower_limit="-0.80" upper_limit="-0.38"/>
                    <measurement group_id="O2" value="-0.72" lower_limit="-0.92" upper_limit="-0.52"/>
                    <measurement group_id="O3" value="-0.89" lower_limit="-1.10" upper_limit="-0.69"/>
                    <measurement group_id="O4" value="-0.83" lower_limit="-1.03" upper_limit="-0.62"/>
                    <measurement group_id="O5" value="-0.08" lower_limit="-0.28" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54 (no participants analyzed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O2" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O3" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O4" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O5" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 106 (no participants analyzed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O2" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O3" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O4" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O5" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 158 (no participants analyzed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O2" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O3" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O4" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O5" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis for change from baseline to Week 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal model</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.80</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis for change from baseline to Week 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal model</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>-0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis for change from baseline to Week 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Contrained longitudinal model</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.10</ci_lower_limit>
            <ci_upper_limit>-0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis for change from baseline to Week 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal model</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Two-hour Post Meal Glucose Level</title>
        <description>Least squares mean change from baseline in 2-hour post meal glucose level.</description>
        <time_frame>Baseline and Weeks 14, 54, 106, and 158</time_frame>
        <population>Full analysis set. The additional participants added to the MK-0941 40 mg and placebo arms to enhance evaluation of safety were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0941 10 mg</title>
            <description>MK-0941 10 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O2">
            <title>MK-0941 20 mg</title>
            <description>MK-0941 20 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O3">
            <title>MK-0941 30 mg</title>
            <description>MK-0941 30 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O4">
            <title>MK-0941 40 mg</title>
            <description>MK-0941 40 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo three times daily plus insulin once daily with or without metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Two-hour Post Meal Glucose Level</title>
          <description>Least squares mean change from baseline in 2-hour post meal glucose level.</description>
          <population>Full analysis set. The additional participants added to the MK-0941 40 mg and placebo arms to enhance evaluation of safety were not included in the analysis.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="115"/>
                <count group_id="O5" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.0" lower_limit="-52.0" upper_limit="-25.1"/>
                    <measurement group_id="O2" value="-29.2" lower_limit="-42.5" upper_limit="-15.9"/>
                    <measurement group_id="O3" value="-37.4" lower_limit="-51.2" upper_limit="-23.6"/>
                    <measurement group_id="O4" value="-39.3" lower_limit="-53.1" upper_limit="-25.5"/>
                    <measurement group_id="O5" value="-2.4" lower_limit="-16.0" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54 (no participants analyzed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O2" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O3" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O4" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O5" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 106 (no participants analyzed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O2" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O3" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O4" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O5" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 158 (no participants analyzed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O2" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O3" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O4" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O5" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis for change from baseline to Week 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudial model</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-36.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-55.6</ci_lower_limit>
            <ci_upper_limit>-17.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis for change from baseline to Week 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Constrained longitudinal model</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-26.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-45.4</ci_lower_limit>
            <ci_upper_limit>-8.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis for change from baseline to Week 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal model</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-35.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-54.0</ci_lower_limit>
            <ci_upper_limit>-16.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis for change from baseline to Week 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal model</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-36.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-55.9</ci_lower_limit>
            <ci_upper_limit>-17.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Fasting Plasma Glucose Level</title>
        <description>Least squares mean change from baseline in fasting plasma glucose.</description>
        <time_frame>Baseline and Weeks 14, 54, 106, and 158</time_frame>
        <population>Full analysis set. The additional participants added to the MK-0941 40 mg and placebo arms to enhance evaluation of safety were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0941 10 mg</title>
            <description>MK-0941 10 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O2">
            <title>MK-0941 20 mg</title>
            <description>MK-0941 20 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O3">
            <title>MK-0941 30 mg</title>
            <description>MK-0941 30 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O4">
            <title>MK-0941 40 mg</title>
            <description>MK-0941 40 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo three times daily plus insulin once daily with or without metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Fasting Plasma Glucose Level</title>
          <description>Least squares mean change from baseline in fasting plasma glucose.</description>
          <population>Full analysis set. The additional participants added to the MK-0941 40 mg and placebo arms to enhance evaluation of safety were not included in the analysis.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="118"/>
                <count group_id="O5" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" lower_limit="-19.9" upper_limit="0.0"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-10.9" upper_limit="7.9"/>
                    <measurement group_id="O3" value="-21.1" lower_limit="-30.9" upper_limit="-11.2"/>
                    <measurement group_id="O4" value="-5.0" lower_limit="-14.9" upper_limit="4.8"/>
                    <measurement group_id="O5" value="-11.8" lower_limit="-21.4" upper_limit="-2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54 (no participants analyzed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O2" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O3" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O4" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O5" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 106 (no participants analyzed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O2" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O3" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O4" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O5" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 158 (no participants analyzed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O2" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O3" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O4" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                    <measurement group_id="O5" value="NA">Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis for change from baseline to Week 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.791</p_value>
            <method>Constrained longitudinal model</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.6</ci_lower_limit>
            <ci_upper_limit>15.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis for change from baseline to Week 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.121</p_value>
            <method>Constrained longitudinal model</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>10.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>23.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis for change from baseline to Week 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.169</p_value>
            <method>Constrained longitudinal model</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-9.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-22.6</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis for change from baseline to Week 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.321</p_value>
            <method>Constrained longitudinal model</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>6.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>20.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieve an HbA1c of &lt;7.0%</title>
        <time_frame>Weeks 106 and 158</time_frame>
        <population>Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 106 or 158</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0941 10 mg</title>
            <description>MK-0941 10 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O2">
            <title>MK-0941 20 mg</title>
            <description>MK-0941 20 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O3">
            <title>MK-0941 30 mg</title>
            <description>MK-0941 30 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O4">
            <title>MK-0941 40 mg</title>
            <description>MK-0941 40 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo three times daily plus insulin once daily with or without metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieve an HbA1c of &lt;7.0%</title>
          <population>Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 106 or 158</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an HbA1c of &lt;7.0% at Week 54 Who Maintain an HbA1c of &lt;7.0%</title>
        <time_frame>Weeks 54, 106 and 158</time_frame>
        <population>Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 106 or 158</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0941 10 mg</title>
            <description>MK-0941 10 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O2">
            <title>MK-0941 20 mg</title>
            <description>MK-0941 20 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O3">
            <title>MK-0941 30 mg</title>
            <description>MK-0941 30 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O4">
            <title>MK-0941 40 mg</title>
            <description>MK-0941 40 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo three times daily plus insulin once daily with or without metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an HbA1c of &lt;7.0% at Week 54 Who Maintain an HbA1c of &lt;7.0%</title>
          <population>Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 106 or 158</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced at Least One Adverse Event</title>
        <time_frame>Entire study including 54-week study and 104-week extension</time_frame>
        <population>Full analysis set. Includes additional participants enrolled in the MK-0941 40 mg and placebo groups to enhance evaluation of the safety profile of MK-0941.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0941 10 mg</title>
            <description>MK-0941 10 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O2">
            <title>MK-0941 20 mg</title>
            <description>MK-0941 20 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O3">
            <title>MK-0941 30 mg</title>
            <description>MK-0941 30 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O4">
            <title>MK-0941 40 mg</title>
            <description>MK-0941 40 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo three times daily plus insulin once daily with or without metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced at Least One Adverse Event</title>
          <population>Full analysis set. Includes additional participants enrolled in the MK-0941 40 mg and placebo groups to enhance evaluation of the safety profile of MK-0941.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="229"/>
                <count group_id="O5" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.7"/>
                    <measurement group_id="O2" value="79.5"/>
                    <measurement group_id="O3" value="80.3"/>
                    <measurement group_id="O4" value="65.5"/>
                    <measurement group_id="O5" value="65.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event</title>
        <time_frame>Entire study including 54-week study and 104-week extension</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MK-0941 10 mg</title>
            <description>MK-0941 10 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O2">
            <title>MK-0941 20 mg</title>
            <description>MK-0941 20 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O3">
            <title>MK-0941 30 mg</title>
            <description>MK-0941 30 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O4">
            <title>MK-0941 40 mg</title>
            <description>MK-0941 40 mg three times daily plus insulin once daily with or without metformin</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo three times daily plus insulin once daily with or without metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="229"/>
                <count group_id="O5" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="5.1"/>
                    <measurement group_id="O3" value="6.8"/>
                    <measurement group_id="O4" value="3.1"/>
                    <measurement group_id="O5" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the entire study including the 54-week study and 104-week extension</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MK-0941 10 mg</title>
          <description>MK-0941 10 mg three times daily plus insulin once daily with or without metformin</description>
        </group>
        <group group_id="E2">
          <title>MK-0941 20 mg</title>
          <description>MK-0941 20 mg three times daily plus insulin once daily with or without metformin</description>
        </group>
        <group group_id="E3">
          <title>MK-0941 30 mg</title>
          <description>MK-0941 30 mg three times daily plus insulin once daily with or without metformin</description>
        </group>
        <group group_id="E4">
          <title>MK-0941 40 mg</title>
          <description>MK-0941 40 mg three times daily plus insulin once daily with or without metformin</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo three times daily plus insulin once daily with or without metformin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Cyst rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer stage 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Colon cancer stage I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Ovarian mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="120" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="101" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="117"/>
                <counts group_id="E3" events="22" subjects_affected="17" subjects_at_risk="117"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="229"/>
                <counts group_id="E5" events="20" subjects_affected="20" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E4" events="13" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E5" events="22" subjects_affected="11" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E4" events="14" subjects_affected="10" subjects_at_risk="229"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="117"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="117"/>
                <counts group_id="E4" events="16" subjects_affected="12" subjects_at_risk="229"/>
                <counts group_id="E5" events="12" subjects_affected="10" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E3" events="16" subjects_affected="11" subjects_at_risk="117"/>
                <counts group_id="E4" events="14" subjects_affected="11" subjects_at_risk="229"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="425" subjects_affected="57" subjects_at_risk="119"/>
                <counts group_id="E2" events="475" subjects_affected="58" subjects_at_risk="117"/>
                <counts group_id="E3" events="719" subjects_affected="57" subjects_at_risk="117"/>
                <counts group_id="E4" events="690" subjects_affected="94" subjects_at_risk="229"/>
                <counts group_id="E5" events="350" subjects_affected="67" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="117"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E4" events="16" subjects_affected="13" subjects_at_risk="229"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

